This might be explained, in part, in accordance with what happens in patients with hematological malignancies, in whom CD8+ T cells seem to compensate the lack of humoral immunity and contribute toward improving outcomes of COVID-19 patients. The gene discussed is CD8A; the disease is hematologic disorder.